{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:33:36Z","timestamp":1752550416356,"version":"3.38.0"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Panniculitides are a group of inflammatory disorders of the subcutaneous fat that have been reported as a rare complication of both a serine threonine kinase BRAF inhibitor monotherapy and BRAF inhibition in combination with a mitogen activated protein kinase (MEK) inhibitor combination therapy used to treat metastatic melanoma. The cutaneous manifestations of BRAF and BRAF\/MEK therapies have been well documented, but neutrophilic panniculitis remains a less common complication with fewer case reports. Physician awareness of this complication when following patients on similar targeted therapies can decrease delays in appropriate management. We report a case of one patient who developed neutrophilic panniculitis during treatment with the BRAF\/MEK combination of dabrafenib and trametinib. We followed the patient from initial presentation in the emergency department to diagnosis to include pathology findings of the disease. In this case of neutrophilic panniculitis, the patient presented with a history of stage IIIa (pT2a N1a M0) cutaneous melanoma of the right flank and developed classic painful nodules on the lower legs and arms with associated fever within the first 2\u2009weeks after initiating adjuvant melanoma targeted therapy. The biopsies showed a mixed, neutrophilic panniculitis, without overlying epidermal changes. Given the patient's clinical history, the biopsy was consistent with a BRAF inhibitor induced neutrophilic panniculitis. The panniculitis resolved with symptomatic care and the patient was maintained on the antitumor therapies.<\/jats:p>","DOI":"10.1111\/cup.14778","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T07:49:08Z","timestamp":1735976948000},"page":"278-283","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neutrophilic Panniculitis Secondary to <scp>BRAF<\/scp> and <scp>MEK<\/scp> Inhibitor Therapy to Treat Stage <scp>IIIa<\/scp> Cutaneous Melanoma"],"prefix":"10.1111","volume":"52","author":[{"given":"Tyra","family":"Reed","sequence":"first","affiliation":[{"name":"Uniformed Services University School of Medicine  Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5672-871X","authenticated-orcid":false,"given":"Steven","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Dermatology San Antonio Uniformed Services Health Consortium (SAUSHEC)  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Dermatology San Antonio Uniformed Services Health Consortium (SAUSHEC)  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Schaffenburg","sequence":"additional","affiliation":[{"name":"Department of Dermatology San Antonio Uniformed Services Health Consortium (SAUSHEC)  San Antonio Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.PAT.0000454078.01547.dd"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001597"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5361569"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.002"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000023"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.12.003"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2023.2205811"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000528"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.14778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T23:20:22Z","timestamp":1741735222000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cup.14778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/cup.14778"],"URL":"https:\/\/doi.org\/10.1111\/cup.14778","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"type":"print","value":"0303-6987"},{"type":"electronic","value":"1600-0560"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"2024-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}